Skip to main content
Top
Published in: Familial Cancer 4/2014

01-12-2014 | Short Communication

Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma

Authors: Alexandre Leon Ribeiro de Ávila, Ana Cristina Victorino Krepischi, Luciana Facure Moredo, Talita Ferreira Marques Aguiar, Felipe Carneiro da Silva, Bianca Costa Soares de Sá, Amanda França de Nóbrega, Maria Isabel Waddington Achatz, João Pedreira Duprat, Gilles Landman, Dirce Maria Carraro

Published in: Familial Cancer | Issue 4/2014

Login to get access

Abstract

Approximately 10 % of all cutaneous melanoma cases occur in a familial context. The major susceptibility gene for familial melanoma is CDKN2A. In Latin America, genetic studies investigating melanoma predisposition are scarce. The aim of this work was to investigate germline CDKN2A point mutations and genomic rearrangements in a cohort of 59 Brazilian melanoma-prone patients. Screening of CDKN2A alterations was performed by sequencing and multiplex ligation probe amplification. Germline CDKN2A mutations affecting p16INK4a were detected in 8 unrelated probands (13.6 %), including 7 familial cases and one patient with multiple melanomas; 4 out of 8 mutation carriers met the criteria for familial melanoma and had multiple primary lesions. Although this study adds to the literature on melanoma susceptibility in Latin America, it is limited by the small size of the cohort. Our findings suggest that stringent inclusion criteria led to a substantially increased rate of CDKN2A mutation detection. This consideration should be taken into account when referring patients for genetic screening in a setting of limited budget, such as in developing countries.
Literature
1.
2.
go back to reference Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9:587–595PubMedCrossRef Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9:587–595PubMedCrossRef
3.
go back to reference Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516PubMedCentralPubMedCrossRef Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516PubMedCentralPubMedCrossRef
4.
go back to reference Kahn HJ, Hanna WM, Chapman JA, Trudeau ME, Lickley HL, Mobbs BG et al (2006) Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 12:294–301PubMedCrossRef Kahn HJ, Hanna WM, Chapman JA, Trudeau ME, Lickley HL, Mobbs BG et al (2006) Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 12:294–301PubMedCrossRef
5.
go back to reference Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedCentralPubMedCrossRef Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedCentralPubMedCrossRef
6.
go back to reference Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41:2040–2059PubMedCrossRef Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41:2040–2059PubMedCrossRef
7.
go back to reference Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W et al (2009) Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 61(677):e1–e14PubMed Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W et al (2009) Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 61(677):e1–e14PubMed
8.
go back to reference Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B (2003) CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Genes Chromosomes Cancer 38:265–268PubMedCrossRef Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B (2003) CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Genes Chromosomes Cancer 38:265–268PubMedCrossRef
10.
go back to reference Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M et al (2013) Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 50:264–270PubMedCentralPubMedCrossRef Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M et al (2013) Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 50:264–270PubMedCentralPubMedCrossRef
11.
go back to reference Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961PubMedCrossRef Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961PubMedCrossRef
12.
go back to reference Ghiorzo P, Bonelli L, Pastorino L, Bruno W, Barile M, Andreotti V et al (2012) MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients. Exp Dermatol 21:718–720PubMedCrossRef Ghiorzo P, Bonelli L, Pastorino L, Bruno W, Barile M, Andreotti V et al (2012) MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients. Exp Dermatol 21:718–720PubMedCrossRef
13.
go back to reference Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V et al (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99–103PubMedCentralPubMedCrossRef Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V et al (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99–103PubMedCentralPubMedCrossRef
14.
go back to reference Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT et al (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99–106PubMedCentralPubMedCrossRef Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT et al (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99–106PubMedCentralPubMedCrossRef
15.
go back to reference Larre Borges A, Borges AL, Cuéllar F, Puig-Butillé JA, Scarone M, Delgado L et al (2009) CDKN2A mutations in melanoma families from Uruguay. Br J Dermatol 161:536–541PubMedCrossRef Larre Borges A, Borges AL, Cuéllar F, Puig-Butillé JA, Scarone M, Delgado L et al (2009) CDKN2A mutations in melanoma families from Uruguay. Br J Dermatol 161:536–541PubMedCrossRef
16.
go back to reference Grazziotin TC, Rey MC, Bica CG, Pinto LA, Bonamigo RR, Puig-Butille JA et al (2013) Genetic variations of patients with familial or multiple melanoma in Southern Brazil. J Eur Acad Dermatol Venereol 27:e179–e185PubMedCrossRef Grazziotin TC, Rey MC, Bica CG, Pinto LA, Bonamigo RR, Puig-Butille JA et al (2013) Genetic variations of patients with familial or multiple melanoma in Southern Brazil. J Eur Acad Dermatol Venereol 27:e179–e185PubMedCrossRef
17.
go back to reference Bakos RM, Besch R, Zoratto GG, Godinho JM, Mazzotti NG, Ruzicka T et al (2011) The CDKN2A p.A148T variant is associated with cutaneous melanoma in Southern Brazil. Exp Dermatol 20(11):890–893PubMedCrossRef Bakos RM, Besch R, Zoratto GG, Godinho JM, Mazzotti NG, Ruzicka T et al (2011) The CDKN2A p.A148T variant is associated with cutaneous melanoma in Southern Brazil. Exp Dermatol 20(11):890–893PubMedCrossRef
18.
go back to reference Ashton-Prolla P, Bakos L, Junqueira G Jr, Giugliani R, Azevedo SJ, Hogg D (2008) Clinical and molecular characterization of patients at risk for hereditary melanoma in southern Brazil. J Invest Dermatol 128(2):421–425PubMed Ashton-Prolla P, Bakos L, Junqueira G Jr, Giugliani R, Azevedo SJ, Hogg D (2008) Clinical and molecular characterization of patients at risk for hereditary melanoma in southern Brazil. J Invest Dermatol 128(2):421–425PubMed
19.
go back to reference Huber J, Ramos ES (2006) The P48T germline mutation and polymorphism in the CDKN2A gene of patients with melanoma. Braz J Med Biol Res 39(2):237–241PubMedCrossRef Huber J, Ramos ES (2006) The P48T germline mutation and polymorphism in the CDKN2A gene of patients with melanoma. Braz J Med Biol Res 39(2):237–241PubMedCrossRef
20.
go back to reference Silva AG, Ewald IP, Sapienza M, Pinheiro M, Peixoto A, de Nóbrega AF et al (2012) Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion. BMC Cancer 12:237PubMedCentralPubMedCrossRef Silva AG, Ewald IP, Sapienza M, Pinheiro M, Peixoto A, de Nóbrega AF et al (2012) Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion. BMC Cancer 12:237PubMedCentralPubMedCrossRef
21.
go back to reference Silva FC, Lisboa BC, Figueiredo MC, Torrezan GT, Santos EM, Krepischi AC et al (2014) Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med Genet 15(1):55PubMedCentralPubMedCrossRef Silva FC, Lisboa BC, Figueiredo MC, Torrezan GT, Santos EM, Krepischi AC et al (2014) Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med Genet 15(1):55PubMedCentralPubMedCrossRef
22.
go back to reference Torrezan GT, da Silva FC, Krepischi AC, Santos E, de O Ferreira F, Rossi BM et al (2011) Breakpoint characterization of a novel large intragenic deletion of MUTYH detected in a MAP patient: case report. BMC Med Genet 12:128PubMedCentralPubMedCrossRef Torrezan GT, da Silva FC, Krepischi AC, Santos E, de O Ferreira F, Rossi BM et al (2011) Breakpoint characterization of a novel large intragenic deletion of MUTYH detected in a MAP patient: case report. BMC Med Genet 12:128PubMedCentralPubMedCrossRef
23.
go back to reference Torrezan GT, Carneiro da Silva FC, Krepischi AC, Monteiro Dos Santos EM, Rossi BM, Carraro DM (2012) A novel SYBR-based duplex qPCR for the detection of gene dosage: detection of an APC large deletion in a familial adenomatous polyposis patient with an unusual phenotype. BMC Med Genet 13:55PubMedCentralPubMedCrossRef Torrezan GT, Carneiro da Silva FC, Krepischi AC, Monteiro Dos Santos EM, Rossi BM, Carraro DM (2012) A novel SYBR-based duplex qPCR for the detection of gene dosage: detection of an APC large deletion in a familial adenomatous polyposis patient with an unusual phenotype. BMC Med Genet 13:55PubMedCentralPubMedCrossRef
24.
go back to reference Krepischi AC, Pearson PL, Rosenberg C (2012) Germline copy number variations and cancer predisposition. Future Oncol 8:441–450PubMedCrossRef Krepischi AC, Pearson PL, Rosenberg C (2012) Germline copy number variations and cancer predisposition. Future Oncol 8:441–450PubMedCrossRef
25.
go back to reference Campos AH, Silva AA, Mota LD, Olivieri ER, Prescinoti VC, Patrão D et al (2012) The value of a tumor bank in the development of cancer research in Brazil: 13 years of experience at the AC Camargo hospital. Biopreserv Biobank 10(2):168–173PubMedCrossRef Campos AH, Silva AA, Mota LD, Olivieri ER, Prescinoti VC, Patrão D et al (2012) The value of a tumor bank in the development of cancer research in Brazil: 13 years of experience at the AC Camargo hospital. Biopreserv Biobank 10(2):168–173PubMedCrossRef
26.
go back to reference Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57PubMedCentralPubMedCrossRef Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57PubMedCentralPubMedCrossRef
27.
go back to reference Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N (1999) Mutation of the CDKN2A 5′-UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128–132PubMedCrossRef Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N (1999) Mutation of the CDKN2A 5′-UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128–132PubMedCrossRef
28.
go back to reference Harland M, Mistry S, Bishop DT, Bishop JA (2001) A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10(23):2679–2686PubMedCrossRef Harland M, Mistry S, Bishop DT, Bishop JA (2001) A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10(23):2679–2686PubMedCrossRef
29.
go back to reference Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S et al (2008) Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 47(2):175–184PubMedCrossRef Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S et al (2008) Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 47(2):175–184PubMedCrossRef
Metadata
Title
Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma
Authors
Alexandre Leon Ribeiro de Ávila
Ana Cristina Victorino Krepischi
Luciana Facure Moredo
Talita Ferreira Marques Aguiar
Felipe Carneiro da Silva
Bianca Costa Soares de Sá
Amanda França de Nóbrega
Maria Isabel Waddington Achatz
João Pedreira Duprat
Gilles Landman
Dirce Maria Carraro
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2014
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9736-1

Other articles of this Issue 4/2014

Familial Cancer 4/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine